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Abstract
Extracellular vesicles (EVs) involved in the intercellular communication hold 
cell-specific cargos that contain proteins, various species of RNA and lipids. EVs 
are emerging as powerful tools for diagnosis and therapy in most diseases but 
little is known about their role in central nervous system (CNS) physiology or 
disease. Considering the extraordinary intricated cytoarchitecture of the brain, 
the implication of EVs in its pathophysiology is difficult to establish. Blood circu-
lating EVs derived from local or distant vascular cells or EVs released from brain 
into the cerebrospinal fluid (CSF) may influence the brain activity. EVs released 
in the blood stream from various tissues may influence the brain by passing 
through the blood-brain barrier (BBB) or through choroid plexus. Since the cho-
roid plexus has also a clearance role, it might be possible that EVs carrying brain 
abnormal proteins to pass into the blood can be detected. Thus, considering that 
EVs are specialized cargos bearing combined signals between cells, they might be 
an interesting therapy target in the future for both regulating neurogenesis and 
abnormal protein clearance. We present here data gathered about EVs that may 
influence the CNS functionality and be involved in most common neurodegen-
erative diseases.
Keywords: extracellular vesicles, exosomes, intercellular communication,  
brain barriers, neurodegenerative diseases
1. Introduction
Extracellular vesicle (EV) is a term used to define a heterogeneous group of 
vesicles isolated from biological fluids or tissues. EVs seem to mediate complex 
cell-to-cell communication over long distances or nearby through various 
macromolecules: polypeptides, various species of RNAs, and/or lipids.  
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The classification of EVs is based on their size and mechanism of biogenesis and 
includes: exosomes, less than 100 nm small vesicles released from multivesicu-
lar bodies after endocytosed materials have been sorted in the endolysosomal 
compartment [1, 2]; ectosomes, up to 500 nm larger vesicles budding from the 
plasma membrane [2, 3]; and multivesicular cargos, consisting of numerous 
vesicles, about 150 nm, enclosed in a plasma membrane-derived shield [4]. 
Although many medical fields experienced real progress with newly discovered 
diagnostic tools or treatments for several diseases, smaller steps are taken in the 
field of cerebrovascular and neurodegenerative diseases. Age-related changes, 
cardiac diseases, and atherosclerosis are known to contribute to the pathogenic 
mechanism of cerebrovascular and neurodegenerative diseases affecting the 
elderly.
2. Biological content of extracellular vesicles
An increasing body of evidence proves that EVs are not only involved in the 
waste disposal system, but, more importantly, they function as membrane-bound 
carriers for intercellular communication [5, 6]. This type of intercellular com-
munication was proven to modulate cellular functions both in homeostatic and 
pathological conditions [6, 7]. High concentrations of EVs were detected in culture 
supernatants and biological fluids [8, 9]. For example, EVs have been isolated from 
CSF and proved to contain overrepresentation of brain-specific proteins derived 
from cerebral white mater and choroid plexus [10]. Several studies demonstrated 
that the level and composition of circulating EVs are altered in disease states, neu-
rodegenerative diseases included [10–12]. Endothelial cells (ECs) and platelets have 
been most studied as sources for EVs [13, 14], but circulating cells as monocytes or 
lymphocytes may also be a source for EVs.
Protein composition of the EV-enclosing membrane, mainly different types of 
integrins, cell adhesion molecules, and tetraspanins, guides the interaction with 
the recipient cells, the targeting, or recruitment once EVs are released into the 
extracellular environment [15]. Specific molecules allow EVs either to interact 
with surface receptors on recipient cells to activate signaling cascades, or to 
promote their docking and uptake. One potential mechanism is direct membrane 
fusion with direct transfer of the cargo molecules into the recipient cytosol [16]. 
Endocytosis, including clathrin-dependent endocytosis, lipid raft-dependent 
pathways, phagocytosis, and even micropinocytosis, was more frequently 
considered [15].
A recent quantitative proteomic analysis allowing comparison of different EV 
subpopulations [17] proved that several classic exosome markers such as flotillin-1, 
heat-shock 70-kDa proteins, actin, and MHC I and II are present in all EV fractions 
obtained by successive centrifugation. Moreover, classic exosomal tetraspanins 
CD9, CD63, and CD81 were unreached in the exosomal fraction but also detected 
in different amounts in larger EVs. The study suggests a further classification of EV 
pelleting at high speed into four subcategories: (a) EVs enriched in all tetraspanins 
and endosome markers (bona fide exosomes); (b) EVs devoid of CD63 and CD81 
but enriched in CD9 (associated with plasma membrane and an early endocytic 
signature); (c) EVs devoid of CD63/CD9/CD81; and (d) EVs enriched in extracel-
lular matrix (ECM) or serum-derived factors. They also propose five categories of 
proteins with different relative distributions in different EV populations that relate 
them to their intracellular source [17]. Thus, exosomes contain ECM proteins, 
receptors, heparin-binding, phospholipid-binding, integrins, immune response, 
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and cell adhesion molecules, while ectosomes are enriched in endoplasmic reticu-
lum proteasome and mitochondrial proteins [9].
The amounts of different lipid classes in EVs have been determined in several 
studies [23, 34], and the enrichment of EV membranes for cholesterol, sphingo-
myelin, glycosphingolipids, and phosphatidylserine compared with their cellular 
sources was proved. However, differences in lipid composition were reported 
between vesicle type and cellular source. Generally, exosomes seem to be enriched 
in glycolipids, phosphatidylserine, and free fatty acids, while ceramides and sphin-
gomyelins were consistently enriched in ectosomes. Still, phosphatidylcholines were 
depleted in exosomes but unchanged or enriched in ectosomes [9].
EVs contain not only proteins and lipids, but several classes of RNAs. Most of 
the recent in vitro studies have proved that EVs contain functional RNA molecules 
that reflect the cellular status and are involved in intercellular crosstalk [18, 19]. 
Different species of RNA have been reported to be enclosed in EVs derived from 
various sources—mRNA, rRNA, and tRNA fragments and especially microRNA 
(miRs) [5]. Several mechanisms for RNA selection, loading into EVs, and their 
uptake by various target cells have been proposed [5, 20]. Packing into EVs protects 
the molecules from RNase degradation once released into the extracellular envi-
ronment. Thus, RNA molecules can be transferred to distant recipient cells, their 
protein production can be modulated [8, 21], or they may be used as predictive bio-
markers for the occurrence of cardiovascular events as demonstrated by the study 
of EVs containing miR-199a and miR-126 in patients with stable coronary artery 
disease [22]. In atherosclerotic disease, miR-containing circulating EVs and apop-
totic bodies, along with other bioactive molecules, are released by proinflammatory 
stimulated monocytes and T cells; ECs and activated platelets initiate hyperplasia 
of vascular smooth muscle cells (VSMCs) which leads to phenotype switching from 
contractile to synthetic and activates their proliferation and migration [23].
Besides membrane proteins and RNA cargo, EVs may contain cytosolic proteins, 
such as cytokines, chemokines, growth factors, enzymes or transcription fac-
tors, functional organelles, and other bioactive molecules such as lipid mediators, 
derived from arachidonic acid [5]. Also, some EVs seem to retain the capacity to 
synthesize eicosanoids using their phospholipid content both by enzymatic and 
nonenzymatic processes [24].
All neural cells from rodent [25, 26] and human [25, 27], even immortalized 
human brain microvascular ECs [25, 28], release EVs which contain mRNA and 
miRs for epigenetic reprogramming of neural cells or post-transcriptional control 
of specific genes [25]. In vitro studies of brain angiogenesis revealed that EVs 
deliver proangiogenic protein, mRNAs, and miRs from cultured glioblastoma cells 
into cerebral ECs [25, 29], especially increased VEGFR-B from immortalized mouse 
cerebral ECs stimulated with LPS and cytokines into targeted cerebral vascular 
pericytes [25, 30]. In vitro and in vivo studies showed that neuronal exosomes 
containing miR-132 could mediate neuronal regulation of brain vascular integrity. 
Thus, in zebrafish larvae and cultured rodent brain cells, it has been shown that 
neurons transfer miR-132, a highly conserved and neuron-enriched miR, via secret-
ing exosomes to ECs to maintain brain vascular integrity. Following translocation to 
ECs through exosome internalization, miR-132 regulates the expression of vascular 
ECs cadherin (VE-cadherin), an important adherens junction protein, by directly 
targeting eukaryotic elongation factor 2 kinase [31]. In addition, two proteins found 
in peripherally circulating plasma EVs, cystatin C and CD14, have been linked to the 
development of brain atrophy and to cerebral white matter lesions, a small vessel 
disease within the brain [32]. Because exosomes contain transferrin and insulin 
receptor [25, 28], which mediate macromolecular passing through the blood-brain 
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barrier (BBB), peripherally infused modified exosomes containing specific RNA 
were used to knockdown a specific gene in mouse brain [32–34]. Considering the 
extraordinary intricate cytoarchitecture of the brain, the presence of EVs in the 
adult brain is hard to be documented. Fetal brain and neurospheres contain cells 
which seem to release vesicles into the extracellular space (Figure 1). EVs are easier 
to be seen near ependymal cells floating in the ventricles from where they can be 
isolated [11].
3. Methods of isolation and analysis of extracellular vesicles
Minimal experimental requirements for definition of EVs and their functions 
have been proposed [35], and isolated EVs should be characterized, and the mor-
phology, protein composition, and functionality should be tested before any new 
enquiries are pursued. Whether the chosen isolation technique for the experiment 
consists in ultracentrifugation or any other technique, after collecting the sample it 
is necessary to perform two low-speed centrifugations as soon as possible after the 
sample collection [36]. The first low-speed centrifugation (300–800×g) removes 
cells, lipid droplets, and macromolecules from the sample, while the second 
low-speed centrifugation (2.500×g) removes platelets and apoptotic bodies. Cell 
removal is an important step; otherwise, the following high-speed centrifugations 
break the cells, leading to EV release and sample contamination [37].
Differential ultracentrifugation is the most widely used method for EV 
isolation [36], which involves multiple centrifugations at increasingly higher 
speeds obtaining a particle separation based on the sedimentation coefficient [38]. 
Establishing the appropriate speed and duration of centrifugation is a very impor-
tant step in EV isolation [36]. Several inconveniences can occur using this technique 
such as the loss of certain subpopulations of EVs or simultaneous isolation of lipo/
protein aggregates [39, 40].
Density gradient ultracentrifugation is a method that isolates the particles 
by size and mass density [41], and its usefulness lies in the fact that it can isolate 
several subpopulations of EVs which are lost using differential ultracentrifugation; 
therefore, it increases the purity of the isolated EVs [42].
Size exclusion chromatography is an easy handling method by which a size-
based separation is achieved [43]. It allows the electron microscopy to be per-
formed immediately after isolation and the proteins and lipoproteins are removed 
Figure 1. 
Transmission electron microscopy of the isolated extracellular vesicles: (A) negative staining and  
(B) cryo-electron microscopy.
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from the sample without losing any subpopulation, thus achieving a high-yield 
separation [44].
Precipitation kits gained a lot of attention during the last years involving a 
concentration method based on the use of polyethylene glycol polymers. The price 
for the kits is low, the protocol is easy to perform, it is compatible with both low 
and high volumes of samples, and the method can be applied on large scale [45]. It 
must be taken into account that the precipitation kits are not the best method for 
EV isolation, having a low-yield purification because of the co-precipitations [37]. 
Anyway, for validating the results, it is recommended to use one of the ultracentri-
fugation methods in parallel with this method.
After the isolation step, a general description of the protein composition 
should be made even though there are no specific EV markers discovered yet. EVs 
are enriched in certain proteins such as tetraspanins (CD63, CD81, and CD9) and 
TSG 101 for exosomes, annexin V for ectosomes, etc. [46]. To exclude a contamina-
tion, the presence or absence of proteins that are not expected to be found in EVs, 
intracellular proteins like calnexin, cytochrome C, histones, GRP94, and Argonaute 
complex must be detected [35]. Western blot, flow cytometry, or mass spectroscopy 
can be used for this protein characterization step.
The next step consists in individual characterization of the EVs using at least 
two methods: electron microscopy [35, 45], atomic force microscopy [47], or 
nanoparticle tracking analysis [48]. Transmission electron microscopy (TEM) 
is the most used method for visualization of EVs considering their nanoscale 
size (Figures 1 and 2). Negative staining [49], TEM on thin section from plastic 
Figure 2. 
Transmission electron microscopy: (A) ependymal cells (EC) facing the ventricular system of the mouse 
brain control the communication between cerebrospinal fluid and brain parenchyma; C—capillary. (B) 
Higher magnification of the square-marked area in (A) shows extracellular vesicles (arrows) close to cilia 
and microvilli of the ependymal cell (EC). Volume transmission may be mediated by multivesicular cargoes 
(encircled) which could be seen released from neurons in fetal mouse brain (C) or neurons from neurospheres 
generated from stem cells (D).
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embedded EVs [49], can also be used to confirm the presence of the lipid bilayer 
of the isolated EV membrane and an election method to investigate EVs in tissue. 
Cryo-TEM [50] is a high resolution method to visualize the lipid bilayer. Electron 
tomography [4, 51] allows 3D reconstruction of the EVs with a very good imaging 
of the different types. For surface protein recognition, immuno-EM [52, 53] allows 
imaging of EV-specific markers.
Flow cytometry is a method based on measuring the signal of the light scatter-
ing from a structure passing through a laser beam. The smaller the particles, the less 
the light scattering, and therefore, conventional cytometry has a detection limit of 
approximately 200 nm [54]. Fluorescence-based detection is used to overcome this 
inconvenience [45, 55], the background noise being higher than the EV signal.
Nanoparticle tracking analysis involves the passing of a laser beam through a 
suspension that contains EVs and the scattering light is captured by a camera [48]. 
The Brownian movement of the EVs in the suspension is recorded, and according to 
their movement, the size can be measured [48].
The last step to fulfill the minimal experimental requirements involves the 
functional assays [35]. Multiple in vitro models can be designed for this step; 
co-incubating EVs with different culture cells and migration, proliferation, coagula-
tion, and fibrinolysis may be quantified depending on the chosen model [45].
There is no gold-standard method yet, but researchers are encouraged to explore 
and to standardize their methods of isolation with the hope that someday, easy EV 
isolation will be possible.
4. Extracellular vesicles and cardiovascular risk for brain pathology
All cells are capable of secreting specific arrays of EVs. Furthermore, the same 
cells may produce EVs by different biogenesis pathways, with different intracellular 
origins, of various sizes, with diverse composition and consequently, different 
functional properties [17]. Crucial feature for the normal functionality of the CNS 
and brain microenvironment homeostasis is sustained by vascular integrity which is 
highly dependent on the systemic status.
Several studies of patients with stable coronary artery disease have reported 
increased levels of circulating EVs which may influence the BBB integrity. Specific 
EV subpopulations, especially those of ECs origin, characterized by CD144+, 
CD131+/annexin A5+, or EVs containing miR-199a and miR-126, are currently 
researched as interesting biomarkers for cardiovascular risk and mortality in these 
patients [22, 56, 57].
Calcifications present in the atherosclerotic plaque [58] have a destabilizing 
effect in early lesions, favoring the rupture, but gain a potential protective effect in 
advanced lesions with heavy calcium deposits [59]. As several studies have shown, 
atherosclerotic plaque calcifications are associated with EVs of ECs, VSMCs, and 
macrophage origin. VSMCs can release EVs with low levels of calcification-inhibit-
ing enzymes and annexin A6/phosphatidylserine nucleation complexes. Exposure 
of VSMCs to proinflammatory cytokines can stimulate the release of EVs that can 
mineralize when inhibitors of calcification are missing [60]. Also, ECs exposed to 
proinflammatory stimuli can release EVs rich in bone morphogenetic protein 2, pro-
moting calcification in VSMs [61]. Alterations in local homeostasis of calcium and 
phosphate lead to the formation of macrophage-derived exosomes which stimulate 
mineralization, through an annexin-dependent mechanism [62].
Recent studies have also noted that in humans, advanced atherosclerotic plaques 
have a high content of procoagulant EVs, originating form leukocytes, erythro-
cytes, and VSMCs [63, 64]. In opposition to ectosomes, exosomes have shown 
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antithrombotic effects. In animal studies, platelet-derived exosomes suppressed 
platelet aggregation and occlusive thrombosis by inhibiting platelet CD36 and 
decreasing CD36-dependent oxidized LDL binding and macrophage cholesterol 
loading [65]. EVs influence the different mechanisms that lead to plaque destabili-
zation and rupture. Intraplaque hemorrhages are produced by neovascularization 
originating from adventitial tissue, stimulated by plaque EVs, such as CD40+ 
vesicles of macrophage origin. Hemorrhages are also favored by leukocyte and 
ECs-EVs with fibrinolytic activity [66, 67]. Fibrous cap weakening is associated 
with VSMC apoptosis, induced by the presence of EVs, released in some pathologi-
cal conditions [100]. Moreover, EVs can influence breakdown of matrix structural 
proteins through metalloproteinase interactions [68].
Circulating levels of procoagulant EVs are higher in patients with acute coronary 
syndromes compared to healthy controls or patients with stable coronary artery 
disease [57, 69]. Circulating EVs alter endothelial-dependent NO mediated vasodila-
tion, and endothelial EVs increase ECs thrombogenicity [70, 71]. Circulating EVs 
have also been investigated as prognostic markers in secondary prevention, in order 
to identify patients at high cardiovascular risk [56, 57]. Increased levels of CD11b+/
CD66+ leukocyte-derived EVs could be useful in identifying asymptomatic patients 
at high risk for plaque rupture [72], while CD3+/CD45+ EVs could identify individu-
als who will develop a major cardiovascular event [73].
All these circulating EVs associated with coronary disease [74] may affect 
the vascular bed of the brain and disrupt the functionality of BBB. Aging and 
cardiovascular-associated disease are associated with BBB alteration [75] and blood 
circulating EVs may mediate early dysfunctions or progression of cerebral associ-
ated pathology. EVs associated with hypercholesterolemia [76] and atherosclerosis 
[77, 78] may have an impact on BBB function, and reducing the proinflammatory 
cytokines enrolling in EVs [79] may be beneficial.
Different neuronal cell types and molecules concur to regulate the improvement 
of brain vasculature [31, 80–82]. Each cell, including neurons and astrocytes [32, 
83], is able to produce EVs enriched in specific proteins, lipids, and RNAs. EVs can 
stimulate targeted neural cells and surrounding neural tissues, which are impor-
tant elements of vascular integrity preservation. The brain pathological condition 
changes the EV content profile of proteins and miRs [84]. A number of studies have 
shown that EVs regulate arterial stiffness [32, 85] which is linked to small vessel 
[32, 86–88], and platelet-derived EVs seem to be important players in the formation 
of cerebral microthrombi which lead to brain atrophy and consequent cognitive 
degeneration. It is believed that the prothrombotic nature of an elevated number of 
platelet-derived EVs reported in the acute phase of cerebral infarction may conduct 
to infarct progression [32, 84, 89, 90]. EV proteins cystatin C and CD14 have been 
shown to be related to cerebral white matter lesions and the progression of brain 
atrophy in patients with manifest vascular disease, suggesting a role for EVs in the 
etiology of structural brain changes [32].
The role of cardiovascular disease risk factors in the occurrence and progression 
of cognitive impairment is widely accepted. There is a link between elevated levels 
of cholesterol and amyloid deposition in the brain, and the relationship between 
atherosclerotic injury and sporadic Alzheimer’s disease is investigated.
5. Extracellular vesicles in neurodegenerative diseases
The pathology of Alzheimer’s disease (AD) consists in the extracellular amyloid 
plaques formed by aggregated amyloid beta peptides and in the intraneuronal 
neurofibrillary tangles made of hyperphosphorylated tau proteins [91]. The 
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accumulation of the proteins induces an apoptotic response with neuronal loss and 
occurs especially in the cerebral cortex [92].
It has been observed that the pathological findings in AD have a typical spatial 
distribution suggesting a neuron-to-neuron spread of the amyloid and hyper-
phosphorylated tau proteins, which promote aggregation, acting as “seeds” [93]. 
Therefore AD is considered to have a prion-like model of propagation [94]. The 
immediate question that rises is: what is the mechanism of the propagation?
Amyloid beta is mainly formed extracellularly from the cleavage of APP by 
beta and gamma secretases, which are found at the level of the plasma membrane 
[95]. But in some degree, the secretases are present in endoplasmic reticulum and 
Golgi apparatus, and there is a certain intracellular production of amyloid beta 
[96]. It is removed from the cell via exosomes embedded in a multivesicular body 
as an alternative pathway to lysosomal degradation [97]. A new study suggests that 
exosomes containing amyloid beta are present in higher concentrations in the AD 
brain compared to the healthy brain [98]. Moreover, the study shows that exosomes 
are the carriers of the toxic amyloid beta from one neuron to another [98]. Also, 
it is thought that exosomes mediate the intercellular transfer of hyperphosphory-
lated tau protein, and the exosome-mediated tau protein induces the formation of 
neurofibrillary tangles [99].
The evolution of AD is insidious with an asymptomatic stage that lasts several 
years [100]. Although asymptomatic, the pathological changes in the brain are 
present in this stage [93]. These findings suggest the value of discovering biomark-
ers that can anticipate the onset of the clinical symptoms or can facilitate a window 
for the possibility of a future therapy that could stop the progression. Amyloid beta 
and hyperphosphorylated tau proteins are of great value as biomarkers when dosed 
from the cerebrospinal fluid [101]. Nevertheless, performing lumbar puncture in a 
wide population is almost impossible. Thereby, the discovery of new biomarkers is a 
valuable research theme.
Several types of miRs isolated from cerebrospinal fluid are differentially 
expressed in AD, such as miR-100, miR-146, miR-505, and miR-1274a [102]. The 
presence of several types of exosomal miRs isolated from serum (miR-361-5p, 
miR-93-5p, miR-335-5p, and miR-30e-5p) correlates with the neuropsychological 
evaluation and brain imaging [103]. It is to be mentioned that exosome-containing 
proteins like tau, apolipoprotein E, cystatin E, and HSP-90 alpha were isolated in 
the cerebrospinal fluid and were present in patients with AD [104]. This evidence 
proposes both miRs and protein-containing exosomes as a promising source of 
biomarkers for AD.
Parkinson’s disease (PD) is a neurodegenerative disease that consists in the loss 
of dopaminergic neurons localized in the substantia nigra [105]. The pathology of 
the disease implies the deposition of Lewy bodies in the neurons which are mostly 
made of misfolded and aggregated alpha-synuclein protein [105]. The Braak staging 
explains the spatio-temporal dissemination of Lewy bodies into the neurons from 
caudal to rostral, starting in the medulla oblongata and spreading to the level of 
the cerebral cortex, damaging various structures on this way [106]. The starting 
point is thought to be either the enteric nervous system or the olfactory bulb [106]. 
Thereby, it is suggested that PD has a prion-like propagation [94]. Are exosomes 
responsible for carrying alpha-synuclein from neuron to neuron? The mechanism 
could be similar to the one described in AD, but there are fewer studies to draw 
certain conclusions regarding the involvement of exosomes in the pathogenesis of 
PD. Excessive intracellular alpha-synuclein is thought to be transported out of the 
cell via multivesicular body containing exosomes in a similar manner as in AD in an 
attempt to clean the intracellular space [107].
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Studies of neuronal cell cultures expressing alpha-synuclein noticed that the 
protein is released by the cell free in the extracellular space but also incorporated 
in the exosomes [108]. Furthermore, neighboring cells take up the exosomes, and 
the transferred alpha-synuclein acts as seed for the formation of the aggregate 
[109]. Evidence to prove that in vivo alpha-synuclein is transferred by exosomes is 
not available yet, but it can be speculated that exosomes play an important role as 
in vitro.
The use of EVs as a biomarker tool in PD is a promising field too [110]. Several 
miRs carried by exosomes were increased in the CSF of PD patients, such as miR-
10a-5p, miR-153, and miR-409-3p, while some miRs such as miR-19b-3p and miR-1 
were significantly reduced [111]. Exosomes containing alpha-synuclein and LRRK 
proteins were also isolated in the CSF of PD patients [109, 112].
6. Extracellular vesicles’ perspective use in brain pathology
The discovery of the EV involvement in several biological processes gave hope 
that some questions regarding neurodegenerative diseases will be answered. First of 
all, it is important to clarify which are the cellular mechanisms involved in the pro-
gression of the disease and if exosomes play any role. Based on the spatio-temporal 
spreading of the pathological proteins in the brain, an appealing theory is the prion-
like propagation theory [113]. It is presumed that exosomes play an important role 
by facilitating the interneuronal transport of the proteins [114]. As well, there is a 
critical need in finding accessible biomarkers that can diagnose a neurodegenerative 
disease in the asymptomatic stage [115]. Dosing certain free proteins in biofluids 
can be an option, but several problems are experienced because of their low concen-
trations [115]. Therefore, a new approach is being attempted consisting in finding 
the proteins encapsulated in extracellular vesicles [116]. Micro-RNAs and different 
proteins carried by exosomes are attractive options for finding new biomarkers in 
several diseases as well as in neurodegenerative diseases [117].
Recently, it was discovered that an important player in the field of neural 
diseases is EV derived from stem cells [118], mainly in the case of stroke [118–120]. 
In stroke pathophysiology, inflammation plays a significant role, circulating 
EV-activating immune cells. Neurons quickly depolarize and die, being next phago-
cytosed by infiltrating circulating macrophages and microglia [84, 121].
Because of their β1 and α2b integrin-enriched content, human neural stem 
cell-derived EV administration recovers both tissue and sensorimotor function and 
may protect the BBB integrity, in the preclinical mouse thromboembolic model 
of stroke [122, 123]. Similarly, multipotent mesenchymal stromal cells (MSCs), 
through their capacity to secrete soluble factors, play an important role in brain 
repair. It was demonstrated that MSC cargos modulate cell signaling in ischemic 
stroke by PI3K/Akt pathway activation [123, 124] and EVs facilitated secretion of 
miRs sustaining MSC neuroprotective effects in ischemic stroke as well. Previous 
research demonstrated that intravenous administration of bone marrow-MSCs 
containing exosomes transferred miR-133b to astrocytes and neurons into the 
ischemic boundary zone [120, 123], and MSCs cultured in the presence of extracts 
from rat ischemic brain induced increased expression of exosomal miR133b [123, 
125]. Also, EVs released by human MSCs seem to have an anti-inflammatory effect 
on mast cells, by increased prostaglandin E2 (PGE2) synthesis and up-regulation of 
EP4 receptor which might prevent the rupture of intracranial aneurysms [126]. All 
these data suggest that EVs from various sources may contribute to the neurogenesis 
and angiogenesis during brain repair processes in cerebral diseases.
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7. Conclusion
The EVs emerge as a powerful tool for early diagnosis and subsequent preven-
tion of pathologies with high risk for the brain dysfunction. Still, EVs investigation 
as biomarkers and therapeutic agents is in its infancy. There is increasing evidence 
that EVs have an important role in brain pathophysiology. Thus, their potential 
application as prognostic and diagnostic biomarkers and targeted therapeutic tools 
relies on their subsequent isolation for molecular and functional characterization 
that can relate them with the cellular source and cellular mechanisms in both health 
and disease.
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